Amarin is now employing 800 reps whose only job it is to market Vascepa...if Amarin gets a standard(i.e. non expedited) revue for the appeal, the decision may not come out until well into 2021...Amarin is a small company with only one product...IMO it would make sense for Amarin to furlough these reps and rehire them, if it makes sense...after the verdict on the appeal is announced.
I'd rather not get the appeal expedited because of too much paperwork filed by AMRN legal than for them to leave stuff out that they may later learn they needed to have to address a line of questioning.